FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286217687> ?p ?o ?g. }

• W4286217687 endingPage "26918" @default.
• W4286217687 startingPage "26905" @default.
• W4286217687 abstract "Aberrant level of ectonucleotide pyrophosphatase/phosphodiesterase-1 and -3 is linked with numerous disorders, for instance, diabetes, cancer, osteoarthritis, chondrocalcinosis, and allergic reactions. These disorders may be cured or minimized by blocking the activity of ENPP1 and ENPP3 isozymes. In this study, arylamide sulphonates were synthesized, characterized, and evaluated for their capability to affect the activity of isozymes ENPP1 and ENPP3. Among the selective inhibitors of ENPP1, compounds 4f and 4q exhibited sub-micromolar IC50 values of 0.28 ± 0.08 and 0.37 ± 0.03 μM, respectively, followed by 7a, with IC50 equal to 0.81 ± 0.05 μM, whereas out of the selective inhibitors of isozyme ENPP3, 4t and 7d preferably lessened the activity to half of the maximal inhibitory concentration of 0.15 ± 0.04 and 0.16 ± 0.01 μM alternatively. In addition, many structures including 4c, 4g, 4k, 4l, 4n, 4o, 4r, 4s, 7b, 7c, and 7e inhibited the activity of both isozymes to a significant level. Enzyme kinetic study of compound 4j revealed an uncompetitive mode of inhibition of ENPP1 isozyme, while 7e competitively blocked the activity of ENPP3. Cell viability analysis revealed the compound 4o as a cytotoxic agent against MCF7 (human breast cancer cell line) with a percentage inhibition of 63.2 ± 2.51%, whereas compounds 4c, 4d, 4n, and 7d decreased the HeLa cell viability (human cervical cancer cell line) to more than 50%. The tested compounds were non-cytotoxic against HEK293 (a human embryonic kidney cell line). Molecular docking analysis of selected inhibitors of both isozymes produced optimistic interactions with the influential amino acids, such as Leu290, Lys295, Tyr340, Asp376, His380, and Pro323 of ENPP1, whereas residues Asn226, His329, Leu239, Tyr289, Pro272, Tyr320, and Ala205 of ENPP3 crystallographic structure formed interactions with the potent inhibitors." @default.
• W4286217687 created "2022-07-21" @default.
• W4286217687 creator A5012615383 @default.
• W4286217687 creator A5022831237 @default.
• W4286217687 creator A5059152576 @default.
• W4286217687 creator A5064038098 @default.
• W4286217687 date "2022-07-19" @default.
• W4286217687 modified "2023-10-17" @default.
• W4286217687 title "Synthesis and Biological Evaluation of Arylamide Sulphonate Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 and -3 Inhibitors" @default.
• W4286217687 cites W1977688661 @default.
• W4286217687 cites W1987229312 @default.
• W4286217687 cites W1995321301 @default.
• W4286217687 cites W2016300311 @default.
• W4286217687 cites W2020883188 @default.
• W4286217687 cites W2020913731 @default.
• W4286217687 cites W2022433703 @default.
• W4286217687 cites W2022832396 @default.
• W4286217687 cites W2035090605 @default.
• W4286217687 cites W2038994554 @default.
• W4286217687 cites W2040512444 @default.
• W4286217687 cites W2055717677 @default.
• W4286217687 cites W2059965072 @default.
• W4286217687 cites W2060356097 @default.
• W4286217687 cites W2060678503 @default.
• W4286217687 cites W2061331632 @default.
• W4286217687 cites W2063329465 @default.
• W4286217687 cites W2084676297 @default.
• W4286217687 cites W2088562619 @default.
• W4286217687 cites W2096597075 @default.
• W4286217687 cites W2118294133 @default.
• W4286217687 cites W2118954181 @default.
• W4286217687 cites W2119273654 @default.
• W4286217687 cites W2128635872 @default.
• W4286217687 cites W2138649565 @default.
• W4286217687 cites W2138664829 @default.
• W4286217687 cites W2139140152 @default.
• W4286217687 cites W2158585939 @default.
• W4286217687 cites W2319745162 @default.
• W4286217687 cites W2334979274 @default.
• W4286217687 cites W2542492166 @default.
• W4286217687 cites W2760411645 @default.
• W4286217687 cites W2801808374 @default.
• W4286217687 cites W2806841040 @default.
• W4286217687 cites W2890340551 @default.
• W4286217687 cites W2942203826 @default.
• W4286217687 cites W2963367782 @default.
• W4286217687 cites W2973812945 @default.
• W4286217687 cites W3074273282 @default.
• W4286217687 cites W3088885404 @default.
• W4286217687 cites W3109317295 @default.
• W4286217687 cites W3112649252 @default.
• W4286217687 cites W3133833201 @default.
• W4286217687 cites W4293247451 @default.
• W4286217687 doi "https://doi.org/10.1021/acsomega.2c03473" @default.
• W4286217687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35936461" @default.
• W4286217687 hasPublicationYear "2022" @default.
• W4286217687 type Work @default.
• W4286217687 citedByCount "3" @default.
• W4286217687 countsByYear W42862176872023 @default.
• W4286217687 crossrefType "journal-article" @default.
• W4286217687 hasAuthorship W4286217687A5012615383 @default.
• W4286217687 hasAuthorship W4286217687A5022831237 @default.
• W4286217687 hasAuthorship W4286217687A5059152576 @default.
• W4286217687 hasAuthorship W4286217687A5064038098 @default.
• W4286217687 hasBestOaLocation W42862176872 @default.
• W4286217687 hasConcept C109316439 @default.
• W4286217687 hasConcept C119795356 @default.
• W4286217687 hasConcept C159110408 @default.
• W4286217687 hasConcept C181199279 @default.
• W4286217687 hasConcept C185592680 @default.
• W4286217687 hasConcept C202751555 @default.
• W4286217687 hasConcept C2777366897 @default.
• W4286217687 hasConcept C2777752497 @default.
• W4286217687 hasConcept C41685203 @default.
• W4286217687 hasConcept C53227056 @default.
• W4286217687 hasConcept C54355233 @default.
• W4286217687 hasConcept C55493867 @default.
• W4286217687 hasConcept C62826618 @default.
• W4286217687 hasConcept C71924100 @default.
• W4286217687 hasConcept C81885089 @default.
• W4286217687 hasConcept C86803240 @default.
• W4286217687 hasConcept C98274493 @default.
• W4286217687 hasConceptScore W4286217687C109316439 @default.
• W4286217687 hasConceptScore W4286217687C119795356 @default.
• W4286217687 hasConceptScore W4286217687C159110408 @default.
• W4286217687 hasConceptScore W4286217687C181199279 @default.
• W4286217687 hasConceptScore W4286217687C185592680 @default.
• W4286217687 hasConceptScore W4286217687C202751555 @default.
• W4286217687 hasConceptScore W4286217687C2777366897 @default.
• W4286217687 hasConceptScore W4286217687C2777752497 @default.
• W4286217687 hasConceptScore W4286217687C41685203 @default.
• W4286217687 hasConceptScore W4286217687C53227056 @default.
• W4286217687 hasConceptScore W4286217687C54355233 @default.
• W4286217687 hasConceptScore W4286217687C55493867 @default.
• W4286217687 hasConceptScore W4286217687C62826618 @default.
• W4286217687 hasConceptScore W4286217687C71924100 @default.
• W4286217687 hasConceptScore W4286217687C81885089 @default.
• W4286217687 hasConceptScore W4286217687C86803240 @default.

• next